Equities analysts expect R1 RCM Inc. (NASDAQ:RCM) to report sales of $337.85 million for the current quarter, according to Zacks. Two analysts have made estimates for R1 RCM’s earnings, with the highest sales estimate coming in at $338.30 million and the lowest estimate coming in at $337.40 million. R1 RCM reported sales of $320.50 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 5.4%. The firm is expected to issue its next earnings report on Tuesday, May 4th.
According to Zacks, analysts expect that R1 RCM will report full year sales of $1.45 billion for the current fiscal year, with estimates ranging from $1.44 billion to $1.46 billion. For the next year, analysts expect that the firm will post sales of $1.67 billion, with estimates ranging from $1.65 billion to $1.70 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for R1 RCM.
R1 RCM (NASDAQ:RCM) last released its quarterly earnings results on Thursday, February 18th. The healthcare provider reported $0.06 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.06. R1 RCM had a net margin of 3.69% and a return on equity of 117.07%. The company had revenue of $328.40 million for the quarter, compared to analyst estimates of $316.65 million.
NASDAQ:RCM opened at $25.83 on Friday. R1 RCM has a 12 month low of $8.34 and a 12 month high of $31.28. The firm has a market cap of $6.75 billion, a price-to-earnings ratio of 287.03, a P/E/G ratio of 4.00 and a beta of 0.91. The company has a quick ratio of 1.59, a current ratio of 1.59 and a debt-to-equity ratio of 8.74. The company’s 50 day moving average is $25.71 and its 200-day moving average is $23.22.
In other news, insider Gary Steven Long sold 5,837 shares of the business’s stock in a transaction on Monday, April 5th. The shares were sold at an average price of $25.13, for a total value of $146,683.81. Following the sale, the insider now owns 214,436 shares in the company, valued at approximately $5,388,776.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO John M. Sparby sold 10,461 shares of the business’s stock in a transaction on Monday, February 22nd. The shares were sold at an average price of $28.07, for a total transaction of $293,640.27. Following the completion of the sale, the chief operating officer now owns 310,854 shares in the company, valued at approximately $8,725,671.78. The disclosure for this sale can be found here. Insiders sold a total of 149,761 shares of company stock worth $4,056,071 in the last three months. Insiders own 59.40% of the company’s stock.
Several large investors have recently modified their holdings of the company. Amalgamated Bank boosted its stake in shares of R1 RCM by 2.4% in the 4th quarter. Amalgamated Bank now owns 17,974 shares of the healthcare provider’s stock valued at $432,000 after purchasing an additional 422 shares in the last quarter. Swiss National Bank lifted its position in R1 RCM by 0.4% during the 4th quarter. Swiss National Bank now owns 222,100 shares of the healthcare provider’s stock worth $5,335,000 after buying an additional 800 shares in the last quarter. Russell Investments Group Ltd. lifted its position in R1 RCM by 1.4% during the 4th quarter. Russell Investments Group Ltd. now owns 77,149 shares of the healthcare provider’s stock worth $1,852,000 after buying an additional 1,083 shares in the last quarter. First Trust Advisors LP lifted its position in R1 RCM by 0.7% during the 4th quarter. First Trust Advisors LP now owns 165,671 shares of the healthcare provider’s stock worth $3,979,000 after buying an additional 1,110 shares in the last quarter. Finally, Barclays PLC lifted its position in R1 RCM by 9,100.0% during the 4th quarter. Barclays PLC now owns 1,656 shares of the healthcare provider’s stock worth $40,000 after buying an additional 1,638 shares in the last quarter. Institutional investors own 81.16% of the company’s stock.
R1 RCM Company Profile
R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers.
Read More: Quiet Period Expirations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.